AzTrials
AzTrials

Acute Respiratory Distress Syndrome (ARDS)APRiCENCT02167698

Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia

A study testing Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation and Methylprednisolone in people with Acute Respiratory Distress Syndrome (ARDS), run by Post Graduate Institute of Medical Education and Research, Chandigarh at 1 site in India.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Read more about this study

Who is it for?
Ages 1 month to 12 years
What is being tested?
Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation and Methylprednisolone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
52 participants
Where
1 siteIndia
Study dates
Feb 2014to Dec 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome:
  • Acute presentation within 1 week of a known clinical insult or new/ worsening respiratory symptoms
  • Bilateral opacities on chest imaging - not fully explained by effusions, lobar/lung collapse, or nodules
  • Respiratory failure is not fully explained by cardiac failure or fluid overload (Echocardiographic assessment to exclude hydrostatic edema)
  • Impaired oxygenation with PaO2/ FiO2 ratio less than 300 or Oxygenation Index greater than 5.3

Who cannot join

  • Greater than 24 hours since diagnosis of ARDS
  • Co-existing raised intra-cranial pressure/ any other condition necessitating use of high dose of sedation (likely to suppress spontaneous breathing)
  • Radiologically confirmed air leak prior to randomization - Pneumothorax/ Pulmonary interstitial Emphysema
  • Clinical evidence of significant airway obstruction/ severe bronchospasm / reactive airway disease
  • Have received mechanical ventilation for more than 72 hours (before meeting inclusion criteria)
  • Symptomatic or uncorrected congenital heart disease or a right to left intra-cardiac shunt
  • Any underlying condition that is likely to impair spontaneous respiratory drive/ efforts (Eg: Brainstem dysfunction, neuromuscular paralysis)
  • Underlying chronic diseases (Eg: Cystic fibrosis, Chronic lung disease, etc)

Trial locations and contacts

1 site in 1 country.

India1 site
  • Pediatric Intensive care unit, Division of Pediatric Critical Care, Advanced Pediatrics Center, Post-graduate Institute of Medical Education & Research

    Chandigarh, 160012

Other trials in India

About this study

Official title: A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome

This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Airway pressure release ventilation (APRV) mode is hypothesized to be superior in terms of lower need for sedation, shorter duration of mechanical ventilation, etc. It is unique and the first worldwide randomized controlled trial on APRV mode in children.

We plan to recruit a minimum of 50 children aged (1 month-12 years) in each group. The study is to be conducted at the Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh between March 2014 to March 2016. This trial would recruit children with respiratory failure and early ARDS and, randomize them to receive either conventional ventilation or the APRV mode. Rest of the supportive care has also been protocolized so that both groups receive treatment as per the existing best practices in every aspect. The primary outcome being studied is the number of ventilator-free days. The secondary outcomes include length of PICU stay, hospital stay, organ-failure free days, 28 day \& 3 month survival, biomarkers of lung injury (IL-6, IL-8, Angiopoeitin-2, soluble-ICAM-1, etc), functional status, Pulmonary function tests, etc. Funding request would be sent to the Indian Council of Medical Research, New Delhi, India.

Assessing lung biomarkers like Interleukin-6 would assess the role of different modes of ventilation in acting as triggers for multi-organ dysfunction as well as for worsening lung injury. This pathbreaking research is likely to open up new avenues upon completion.

Read the detailed description

Study setting:

15-bedded pediatric intensive care unit (PICU) of a multi-specialty, tertiary referral and teaching hospital- the Advanced Pediatrics Centre (APC) in Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Study period Recruitment: January 2014 to December 2016 Data Analysis: Jan 2017 to June 2017 Study design An open-labelled, parallel-arm, efficacy/feasibility randomized controlled trial Ethics approval Ethics approval has been obtained from the Institute Ethics Committee. The study has been registered with Clinical Trials Registry - India (CTRI) (ctri.nic.in). Informed consent will be obtained from the parents/legal guardian and the conversation would be recorded using a camera (audio-visual documentation of evidence).

Sample size estimation Assuming alpha error of 5% and power of 80% with non-inferiority limit of 4 days (Standard deviation of VFDs being 8.2 days in the conventional low tidal volume ventilation group in pilot trial), sample size was calculated to be 52 per group. As this is a safety and feasibility trial, an interim analysis would be done at 50% enrolment.

Enrolment Parents or legal guardians of children who satisfy the above eligibility criteria will be invited by the investigator to participate in the study. Parents are free not to participate, or to withdraw from the study at any point of time. All children, irrespective of their enrollment in the study, will receive standard pediatric intensive care unit (PICU) care as per the unit's existing protocol. An information sheet (in Hindi/ English) furnishing details of the study will be provided to the parents. Given the fact that all these children are sedated and on mechanical ventilation, obtaining assent would not be feasible in this study.

Randomization Sequence generation A computer-generated, unstratified, block randomization with variable block sizes will be performed to determine group allocation. A person not involved in the study will perform the random number allocation and prepare opaque, sealed envelopes containing the allocation.

Concealment allocation Each pre-sealed opaque envelope would be opened only after obtaining a written consent and audio-visual record of the same. As the randomization is done using a variable block size, and prepared by a statistician not directly involved in the study, there would be no way of predicting the random allocation, thus minimizing the risk of allocation bias.

Randomization implementation After parents provide informed consent, randomization would be done within the next one hour and child initiated on appropriate mode of ventilation. The supportive care for both the groups, would be as per the attached supplementary protocols

Intervention protocol:

The Airway pressure release ventilation (APRV) intervention protocol has been designed based on the available APRV literature as of Dec 2013.

Start the child on APRV mode of ventilation with the following settings:

  • P HIGH would determine the degree of baseline lung inflation. A rough estimate can be obtained based on the plateau pressure requirements on the conventional mode of ventilation. Perform an inspiratory hold to ascertain the plateau pressures:
  • If P plateau > 30 cm water, set P HIGH at 30 cm water
  • If P plateau < 30 cm water, set P HIGH at or 1-2 cm above the measured P plateau.
  • Alternatively, if P plateau cannot be measured, P HIGH can be set according to the following guide:

PaO2/ FiO2 ratio P High < 250 15-20 < 200 20-25 < 150 25-28

After initiating a particular P HIGH, a clinical assessment of lung volume needs to be followed with a chest radiograph to determine the degree of lung inflation (similar to setting of Mean airway pressure in High frequency oscillatory mode of ventilation). The child's P HIGH is adjusted to maintain optimal lung volume, without clinical or radiological evidence of hyperinflation: no signs of decreased cardiac output/ hypotension and/or the level of the diaphragm visible greater than the ninth rib.

  • Start at T High of 4 seconds; Titrate T High based on oxygenation status. At least 80 -95% of the total cycle time should be spent in T High.
  • Set P Low at Zero cm H2O
  • Set T Low so that expiratory flow decreases by 25 % of peak expiratory flow rate (PEFR); usually 0.1-0.8 seconds. The ratio of T-PEFR to PEFR should be targeted near 75%. This entity needs to be titrated every 2-4 hours and may have to be shortened as lung injury advances.
  • Set Pressure Support at ZERO
  • The number of breaths per minute or number of releases is a function of T High and T Low as depicted below:

Weaning from APRV would also be carried out in a structured, protocolized manner. The following strategies would be adopted:

  1. As child's clinical condition and oxygenation index improves, and Fraction of inspired oxygen levels are brought down to 0.6, T HIGH is increased in steps of 0.5-2 seconds till it is 10-12 seconds.
  2. P HIGH can be subsequently decreased in steps of 2-3 cm H2O till a value of 12-16 is reached. Decrease in P HIGH can be carried out earlier if features of hyperinflation (clinical/radiological) appear at any point.
  3. The goal is to reach pressure levels of 12-16 cm H2O and then switch to Continuous positive airway pressure (CPAP) of 6-8 cm H2O, from which child can be extubated directly to nasal prong CPAP or gradually tapered off CPAP to Endotracheal-T piece and subsequently extubated depending on the overall clinical status.
Being tested
Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation, Methylprednisolone, Restrictive fluid therapy, sedo-analgesia titration
Keywords
Pediatric acute respiratory distress syndrome, Mechanical ventilation, Airway pressure release ventilation, Conventional low-tidal volume ventilation
Medical subject headings
Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Airway Pressure Release Ventilation (APRV)Device

    Also called BiLevel, BiPAP

    This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation

  • Low-tidal volume ventilationOther

    Also called Lung-protective ventilation

    This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.

  • MethylprednisoloneDrug

    Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.

  • Restrictive fluid therapyOther

    Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols

  • sedo-analgesia titrationDrug

  • Protocolized early enteral nutritionOther

    Early enteral nutrition and attempt to meet calorie-protein goals

  • Protocolized supportive careOther

    Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care

  • Biomarker AssayOther

    Also called Interleukin 6, Interleukin 8, Angiopoeitin-2, soluble-ICAM-1

    Biomarker Assay for patients in both arms

Study groups in NCT02167698
Study groupRoleWhat they receive
Airway pressure release ventilation armExperimentalThis group of children would be ventilated using the Airway pressure release ventilation (APRV) mode. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups.
Receives: Device: Airway Pressure Release Ventilation (APRV); Drug: Methylprednisolone; Other: Restrictive fluid therapy; Drug: sedo-analgesia titration; Other: Protocolized early enteral nutrition; Other: Protocolized supportive care; Other: Biomarker Assay
Low-tidal volume ventilation armActive comparatorLow-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
Receives: Other: Low-tidal volume ventilation; Drug: Methylprednisolone; Other: Restrictive fluid therapy; Drug: sedo-analgesia titration; Other: Protocolized early enteral nutrition; Other: Protocolized supportive care; Other: Biomarker Assay

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Twenty-eight-day ventilator-free days

    Measured: 28 days

Secondary outcomes (23)
  1. Twenty-eight-day survival

    Measured: 28 days

  2. Length of PICU stay

    The children would be followed up for the duration of their PICU stay

    Measured: Up to 3 months

  3. Organ-failure-free-days

    Measured: 28 days

  4. Time-to-recovery of lung injury

    Number of days for recovery of lung injury (OI<5).

    Measured: Up to 28 days

  5. Number of children with adverse events

    Children would be observed for incidence of adverse events during the period of PICU stay/ ventilation

    Measured: 3 years

  6. All-cause mortality

    Measured: Three months

  7. Spirometry

    Forced Expiratory volume during 1st second/ Forced vital capacity

    Measured: 3 months

  8. Pediatric Cerebral performance category

    Functional outcomes

    Measured: 6 Months

  9. Pediatric Overall performance category

    Measured: 6 months

  10. Spirometry

    Forced Expiratory Volume during 1st second / Forced Vital Capacity

    Measured: 6 months

  11. Pediatric overall performance category

    Assessment of functional outcomes

    Measured: 3 months

  12. Pediatric cerebral performance category

    Assessment of functional outcomes

    Measured: 3 months

  13. Interleukin-6 levels

    Measured: 72 hours of enrolment

  14. Arterial lactate levels

    Measured: 72 hours

  15. Percentage reduction in 'oxygenation Index'

    Percentage improvement in oxygenation index at 6 hours of enrolment

    Measured: 6 hours

  16. Radiological score

    Measured: 48 hours

  17. Duration of inotropic requirement

    Average time frame

    Measured: up to 7 days

  18. Vaso-active inotropic score

    Measured: 72 hours

  19. Cumulative dose of sedation

    Measured: 7 days

  20. Cumulative dose of analgesic

    Measured: 7 days

  21. Cumulative dose of neuromuscular blocking agent

    Measured: 7 days

  22. Requirement for renal replacement therapy

    Need for renal replacement therapy in the first 28 days of PICu stay or discharge/ death whichever is earlier

    Measured: 28 days

  23. Pediatric Logistic Organ Dysfunction (PELOD) score

    Measured: 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jun 2014 (estimated)
  2. Study startFeb 2014
  3. Primary completionJun 2016
  4. Study completionDec 2016

Why it stopped: Increased mortality in the intervention arm at 50% enrolment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
52 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02167698
Sponsor's protocol ID
CTRI/2014/06/004677
Other IDs
CTRI/2014/06/004677
Acronym
APRiCE
Status last verified
May 2017
First submitted
16 Jun 2014
Last updated
19 May 2017
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided: Permission would have to be sought from institution in this regard.

Publications

  • Andrews P, Habashi N. Airway pressure release ventilation. Curr Probl Surg. 2013 Oct;50(10):462-70. doi: 10.1067/j.cpsurg.2013.08.010. No abstract available.

    PubMed 24156844
  • Andrews PL, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O'Toole RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of airway pressure release ventilation may reduce mortality in high-risk trauma patients: a systematic review of observational trauma ARDS literature. J Trauma Acute Care Surg. 2013 Oct;75(4):635-41. doi: 10.1097/TA.0b013e31829d3504.

    PubMed 24064877
  • Emr B, Gatto LA, Roy S, Satalin J, Ghosh A, Snyder K, Andrews P, Habashi N, Marx W, Ge L, Wang G, Dean DA, Vodovotz Y, Nieman G. Airway pressure release ventilation prevents ventilator-induced lung injury in normal lungs. JAMA Surg. 2013 Nov;148(11):1005-12. doi: 10.1001/jamasurg.2013.3746.

    PubMed 24026214
  • Roy SK, Emr B, Sadowitz B, Gatto LA, Ghosh A, Satalin JM, Snyder KP, Ge L, Wang G, Marx W, Dean D, Andrews P, Singh A, Scalea T, Habashi N, Nieman GF. Preemptive application of airway pressure release ventilation prevents development of acute respiratory distress syndrome in a rat traumatic hemorrhagic shock model. Shock. 2013 Sep;40(3):210-6. doi: 10.1097/SHK.0b013e31829efb06.

    PubMed 23799354
  • Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P, Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y, Nieman G. Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. Shock. 2013 Jan;39(1):28-38. doi: 10.1097/SHK.0b013e31827b47bb.

    PubMed 23247119
  • Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1199-1207. doi: 10.1164/rccm.201705-0989OC.

    PubMed 29641221

Questions about this trial

What is this clinical trial studying?

A study testing Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation and Methylprednisolone in people with Acute Respiratory Distress Syndrome (ARDS), run by Post Graduate Institute of Medical Education and Research, Chandigarh at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Increased mortality in the intervention arm at 50% enrolment). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Twenty-eight-day ventilator-free days (time frame: 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02167698, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in